INTRODUCTION
The α4β1 integrin is a recognized cell-surface receptor for the plasma and matrix protein fibronectin (Fn) and the endothelial cell receptor VCAM-1 (1) , and these interactions are widely assumed to play an important role in leukocyte physiology (2) and blood cell maturation (3) (4) (5) . Unlike many integrins, α4β1 binds to these ligands in an RGD-independent manner (6) (7) (8) . However, this integrin can also interact with Fn in an RGD-dependent manner (9) .
The α4β1 integrin is suspected to assume multiple "activation" states (10;11) . Consistent with our expanding knowledge of integrin physiology, the activation state of α4β1 may be regulated by several factors, including divalent cation concentration and agonistinduced "inside-out" cell-signaling (12;13), which could induce the conversion of α4β1 to an active conformation. Recently, the α4 cytoplasmic domain has been demonstrated to be directly phosphorylated in vitro by cAMP-dependent protein kinase A (PKA) (14) , suggesting that activation of PKA could impact the activation state of α4β1. Activation of α4β1, as with other integrins, may also confer the ability of this integrin to bind additional ligands. For instance, although α4β1 is not a well-characterized thrombospondin (TSP) receptor, an 4 vessel wall or circulate in plasma (18) . SS RBC adhesion to the α4β1 ligands TSP, VCAM-1 and Fn or other factors in the vasculature may dramatically impact vaso-occlusion. Either soluble TSP, which is abnormally elevated in the plasma of SCD patients (21) or soluble Fn, may serve as a "tether" to anchor circulating SS RBCs to vascular endothelium (22;23) , monocytes (24) , and platelets (25) . TSP is also present in the subendothelial matrix and is exposed to flowing blood at sites of vascular injury. This exposed TSP potentially serves to anchor SS RBCs to the vascular wall. The resulting adhesion of SS RBCs to the endothelium and/or vascular proteins in the blood vessel is likely to slow or stop blood flow. Furthermore, the in vitro adhesivity of a SCD patient's cells has been positively correlated to the severity of their disease (26) .
In an effort to better understand the mechanism(s) of SS RBC interaction with the matrix and plasma molecule TSP, we recently identified CD47, a known receptor for soluble TSP, as a potent signaling receptor on SS RBCs that upon engagement by soluble TSP, activates intracellular signaling events, resulting in SS RBC adhesion to immobilized TSP markedly above basal levels (27) . These results pointed to a novel mechanism of activated, agonistinduced SS RBC adhesion to TSP and potentially other vascular proteins. However, the CD47-activated adhesion receptor on SS RBCs that mediates this stimulated adhesion to immobilized TSP remained unknown.
Classically, CD47 associates with integrins and activates integrin-dependent adhesion in other hematopoietic cells (28) . In platelets, CD47 co-immunoprecipitates with, and activates both integrin αIIbβ3 (29) and α2β1 (30) . In other cell lines, CD47 activates integrins αvβ3 and α4β1 (15;31) . While circulating mature erythrocytes have lost integrin expression, we and others have shown that α4β1 expression persists and is the only integrin present on circulating by guest on October 5, 2017 http://www.jbc.org/ Downloaded from immature sickle RBCs (32;33) . Thus, SS RBCs provide an excellent model to unravel α4β1 biochemistry, as these cells allow for the isolated study of this integrin in an abundant, pathophysiologically relevant system.
We have demonstrated that the reticulocyte population of circulating SS RBCs is the most responsive to CD47-stimulated adhesion to TSP (27) . Other studies have demonstrated that increased reticulocyte count correlates with SCD severity (34) ; therefore the combination of increased soluble TSP levels, reticulocytosis, and the capacity of CD47 to initiate signaling in SS RBCs could provide a potent mechanism through which SS RBC adhesion could promote vaso-occlusion in vivo.
Given the unrealized binding and activation potential of α4β1 on SS RBCs, we asked whether this integrin was the unknown receptor for immobilized TSP. We now show that α4β1 is the TSP receptor that becomes activated upon CD47-induced stimulation of SS RBCs.
Furthermore, the CD47-activated α4β1 on these cells exhibits an unusual combination of adhesive properties by requiring both the N-terminal domain of TSP as well as the more Cterminal RGD site in this molecule. CD47-activated α4β1 on SS RBCs also recognizes soluble Fn in an RGD-dependent manner. However, CD47 signaling promotes SS RBC adhesion to immobilized VCAM-1 in an RGD-independent manner. Furthermore, we demonstrate that CD47 and α4β1 are complexed on the surface of SS RBCs and that efficient α4β1-mediated adhesion, as with several other integrins (35;36) requires cytoskeletal remodeling. We have elucidated part of the mechanism of CD47-induced, α4β1-mediated adhesion and integrin activation in these cells and show that CD47-mediated activation of α4β1 requires a PKAdependent phosphorylation of the α4 cytoplasmic domain that occurs without a measurable increase in cAMP above basal levels. The activation of α4β1 is also dependent on the activity 6 of the large G-protein Gi, but may be mediated by Gi activation of the Src family of tyrosine kinases rather than by a direct coupling of Gi to adenylyl cyclase. Taken together, our results further reinforce the importance of α4β1 as a therapeutic target in SCD.
Experimental Procedures
Reagents Human purified recombinant VCAM-1 was obtained from R&D Biosciences (Raleigh, NC), purified platelet TSP was obtained from Sigma (St. Louis, MO) and purified plasma Fn was obtained from Gibco (Grand Island, NY). The anti-CD47 monoclonal antibody, IF7, was a generous gift from Eric Brown, UCSF (37 
Flow adhesion assay and protein immobilization
The flow adhesion system used for this study was designed to mimic blood flow through postcapillary venules as previously described (38) . Briefly, purified TSP (18.75 ng/ml), VCAM-1 (50 µg/ml) or the NoC1 peptide (50 µg/ml) in perfusion media was immobilized onto identical wells formed by a silicon gasket in a 35 mm polystyrene culture dish by incubating for 2 h at 37°C. A 1% hematocrit solution and blotted with an anti-CD47 mAb, B6H12. For α4 cytoplasmic domain phosphorylation studies, washed SS RBCs were pretreated with 19 ng/ml okadaic acid (37°C, 120 min), lysed in lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM EDTA, 1% Triton X-100, 0.05% Tween 20, 2 µg/ml aprotinin, 40 µg/ml bestatin, 0.5 µg/ml leupeptin, 0.7 µg/ml pepstatin, 0.5 mM Pefabloc, 20 mM glycerophosphate, 50 µM sodium vanadate, 1 mM NaF, 10 mM pnitrophenol phosphate) (39) and incubated as before with an anti-α4 antibody from Chemicon (20 µg/ml), followed by SDS-PAGE and transfer to PVDF membranes. Membranes were then
Western blotted with α-PSα4, a monoclonal antibody raised against the serine 988 -phosphorylated form of the cytoplasmic domain of the α4 integrin (14) .
Determination of cAMP levels in SS RBCs cAMP levels in SS RBCs were determined exactly as described previously (40) .
Conformational studies with immobilized TSP To determine if the RGD site in TSP is exposed upon protein immobilization, 18.75 ng/ml of TSP were allowed to adhere for two h at 37°C in Tris buffered saline (TBS) supplemented with 2 mM Ca 2+ in microtiter wells (Falcon).
The wells were washed and then either reduced with β-mercaptoethanol for 1 h at room temperature or maintained in the Ca 2+ -supplemented TBS. The wells were subjected to ELISA using either the D4.6 antibody or the MA1 antibody at a final concentration of 1 µg/ml followed by anti-mouse secondary antibody conjugated to HRP (Amersham Biosciences, San
Francisco, CA). The samples were then developed using TMB substrate and read by Spectra
Max Plus (Molecular Devices, Sunnyvale, CA) microplate reader.
Immunoprecipitation of TSP from SS patient plasma. SS patient samples were drawn
into PPACK anticoagulant to maintain Ca 2+ levels and platelet poor-plasma was obtained by immediate centrifugation at 150 g to separate platelet-rich plasma from RBCs and WBCs. The platelet-rich plasma was then incubated with 40 ng/ml PGI 2 to prevent platelet activation and release and then centrifuged at 200 g to remove platelets. The TSP antibody D4.6 or C6.7 (1 µg/ml final concentration) was then added to the platelet-poor plasma and incubated for 2 h at room temperature followed by the addition of 30 µl of a 50% slurry of protein G-agarose Statistics The signifigance of any differences for all treatments studied was determined using a two-tailed student's t-test. Unless otherwise noted, P<0.001. (Fig 1a) . Incubation with sub-maximal concentrations of the α4 and β1 blocking mAbs in combination also completely blocked TSP-stimulated adhesion to TSP (Fig 1a) . These results suggest that each integrin subunit contributed to the stimulated SS RBC adhesion. However, neither antibody alone or in combination had any effect on basal SS RBC adhesion to TSP (data not shown). Similar results as above were obtained when SS RBCs were stimulated with the 4N1K agonist peptide derived from TSP (data not shown). These data implicate a specific role for α4β1 as the integrin on SS RBCs that mediates CD47-stimulated adhesion to immobilized TSP.
RESULTS

We previously reported that stimulation of CD47 on SS
In myeloid cell lines, CD47-stimulated α4β1 binds to the heparin-binding domain at the N-terminus of TSP; we therefore evaluated CD47-stimulated SS RBC adhesion to a peptide derived from the N-terminus of TSP termed the NoC1 peptide (15) . Our data indicate that SS RBCs stimulated with the 4N1K peptide adhered to the NoC1 peptide and this adhesion could be completely blocked by an α4 or β1 function-blocking antibody, but not a control IgG (Fig   1b) . However, even at saturating concentrations of immobilized NoC1 peptide (Fig 1b) , the degree to which the 4N1K-stimulated SS RBCs adhered was substantially less than the degree to which they adhered to the intact TSP molecule (Fig 1a) , suggesting that the NoC1 peptide could not fully recapitulate SS RBC adhesion to intact TSP. In addition, incubation of CD47-stimulated SS RBCs with soluble NoC1 peptide completely blocked stimulated SS RBC adhesion to intact TSP (Fig 1a) . These results indicate that CD47-stimulated SS RBCs bind at least in part to the sequence of immobilized TSP defined by the NoC1 peptide. An LDV conjugate, representative of a class of inhibitors known to block α4β1 function, failed to inhibit the α4β1-mediated adhesion to either TSP or the NoC1 peptide (Fig 1a and 1b, respectively) , even though both TSP and NoC1 contain an LDV sequence that has been implicated in α4β1-mediated adhesion to other ligands (45) .
Although α4β1 is typically identified as a non-RGD binding integrin, α4β1 can mediate RGD-dependent interactions with its ligands (9) . In addition, α4β1 is typically identified as a receptor for VCAM-1 and Fn, but, when activated, can also bind TSP (46) . A role for α4β1 as an activated, RGD-dependent receptor for TSP on any cell type had never been evaluated.
We therefore asked whether the CD47-induced increase in SS RBC adhesion to immobilized TSP under shear was also RGD-dependent. We found that an RGD (100µM), but not a control RGE peptide completely blocked the TSP-stimulated portion of SS RBC adhesion to immobilized TSP (Fig 2a, left) . Similar results were obtained when SS RBCs were stimulated with the 4N1K agonist peptide (Fig 2a, right) . Because the RGD peptide could potentially interfere with either soluble TSP or 4N1K binding to CD47, we also stimulated SS RBC adhesion to immobilized TSP with the B6H12 mAb, which in SS RBCs and some other cells, activates CD47 signaling (15;27;47) . Under these conditions, the RGD peptide still blocked SS RBC adhesion to TSP (data not shown). Neither RGD nor RGE had any effect on basal, nonstimulated adhesion to immobilized TSP under shear (data not shown). Unlike the NoC1 peptide, the RGD peptide, when immobilized, failed to support CD47-stimulated SS RBC adhesion (data not shown). However, simultaneous immobilization of NoC1 and the RGD peptide fully reconstituted SS RBC adhesion to the level observed with intact TSP (Fig 1b) , further reinforcing a role for the RGD site within TSP in maintaining efficient SS RBC adhesion under shear conditions. However, incubation of the stimulated RBCs with a soluble RGD peptide failed to inhibit the α4β1-mediated adhesion to the NoC1 peptide (Fig 1b) indicating that α4β1 independently binds to both sites in the intact TSP protein under shear conditions.
These results suggest that activation of α4β1 on SS RBCs by CD47 induces SS RBC adhesion to immobilized TSP that requires both the N-terminus and RGD-containing regions of immobilized TSP.
Even though immobilized TSP can support cell adhesion via its RGD site (48) , several studies have reported that the RGD peptide sequence is cryptic in intact TSP and may require TSP to be either reduced or denatured before the RGD site is available for binding (49) .
Therefore, we next sought to determine if the RGD site was accessible to α4β1 in either the immobilized or soluble forms of intact TSP. We first examined the exposure of the RGD site in TSP present in platelet-poor plasma derived from sickle cell patients. It should be noted that plasma levels of TSP are abnormally elevated in SCD (21) . Endogenous plasma TSP from these patients was immunoprecipitated with saturating amounts of either the nonconformationally specific antibody C6.7, against the C-terminal CD47 binding domain of TSP (50) , or the comformationally specific antibody D4.6, that binds near the RGD-containing region of TSP and whose epitope is both Ca
2+
-and redox-sensitive in TSP (51;52). As shown by Western blotting analysis of the immunoprecipitates, (Fig 2b) , the D4.6 antibody recognized plasma TSP poorly compared to the C6.7 antibody. However, when the platelet poor plasma was subjected to mild reducing conditions, both mAbs effectively immunoprecipitated equivalent amounts of TSP, suggesting that the D4.6 epitope becomes available on reduced TSP. These results suggest that, in sickle cell plasma, the RGD site near the D4.6 epitope in soluble TSP is relatively cryptic, but the C-terminal portion of TSP, which contains the C6.7
epitope and the CD47 binding site, is exposed and available to bind CD47. We next asked whether immobilization of TSP was sufficient to expose the RGD site in the molecule by adhering reduced and non-reduced TSP to microtiter wells and subjecting samples to ELISA using the D4.6 mAb, or MAI, another conformationally specific mAb against TSP (53) . Both antibodies bound equally well to reduced or non-reduced, immobilized TSP, suggesting that immobilization exposes the RGD site in TSP as efficiently as mild reduction of the molecule (Fig 2c) .
To further confirm that α4β1-mediated adhesion was stimulated by CD47 on SS RBCs, we evaluated CD47-induced SS RBC adhesion to a known ligand for α4β1, VCAM-1.
Unstimulated SS RBCs adhered poorly to immobilized, purified VCAM-1 under basal shear conditions (Fig 3a) . However, both soluble TSP and 4N1K induced marked SS RBC adhesion to immobilized VCAM-1. Furthermore, pre-incubation of SS RBCs with 1F7, a function blocking mAb against CD47, but not an isotype-matched control antibody, completely blocked either TSP-or 4N1K-induced SS RBC adhesion to VCAM-1, indicating that CD47 is the agonist receptor responsible for the induced adhesion (Fig 3a) . Likewise, this CD47-induced SS RBC adhesion to VCAM-1 was blocked by function blocking antibodies against α4 and β1
either alone (Fig 3b) or in combination (data not shown). CD47-induced adhesion to immobilized VCAM-1, unlike immobilized TSP, was insensitive to RGD inhibition, but was completely inhibited by the LDV compound (Fig 3b) . Taken together, these results suggest that CD47 induces an increased affinity and/or avidity of α4β1 for VCAM-1 and TSP.
However, while CD47 induced an NoC1 and RGD-dependent interaction of α4β1 with immobilized TSP, CD47 induced a strictly RGD-independent interaction of α4β1 to immobilized VCAM-1 (Fig 3b) . Thus, these results suggest that CD47-stimulated α4β1 not only mediates adhesion to several ligands relevant to SCD, but also recognizes these ligands via distinct mechanisms. signaling (Fig 4b) , whereas an isotype-matched control IgG was without effect (data not shown). Furthermore, the increased soluble Fn binding was blocked by either an α4 or β1
subunit-specific function-blocking antibody (Fig 4c) , demonstrating an α4β1-dependent an RGD-containing peptide ablated Fn binding whereas the control RGE peptide was without effect (Fig 4d) . The data therefore indicate that CD47-induces inside-out signaling in SS RBCs, which activates α4β1 and renders this integrin capable of binding soluble ligand.
We next sought to examine the "inside-out" signaling pathway through which CD47
induces α4β1-mediated adhesion in SS RBCs. To this end, we analyzed the phosphorylation state of the α4 subunit cytoplasmic domain in response to either 4N1K-or TSP-induced CD47
signaling. Phosphorylation of the α4 cytoplasmic domain has been shown to regulate its interaction with the cytoskeletal protein, paxillin (39) and may affect the adhesive function of α4β1 (12) . To detect phosphorylation of the α4 cytoplasmic domain in SS RBCs, we used α-PSα4, a well-characterized mAb specific for the serine 988 -phosphorylated form of the α4 cytoplasmic domain (14) . While basal levels of α4 phosphorylation in SS RBCs were not detectable (Fig 5a) , both stimulation with the 4N1K peptide and, to a lesser extent, soluble TSP, induced phosphorylation of the α4 cytoplasmic domain in SS RBCs (Fig 5a) . B6H12 also induced α4 cytoplasmic domain phosphorylation, whereas an IgG control antibody was much less efficient (Fig 5a) , although similar amounts of the α4 integrin were present in each lane (Fig 5a, bottom panel) . These data suggest that CD47 activation promotes serine phosphorylation of this integrin, thus potentially regulating its affinity for ligands.
Previous studies have suggested that phosphorylation of the α4 cytoplasmic domain occurs within a PKA consensus site (14;39). We therefore asked if CD47-induced phosphorylation of the α4 cytoplasmic domain in SS RBCs was dependent on PKA activity.
We found that α4 phosphorylation was completely blocked by pre-incubation of SS RBCs with the PKA inhibitor, PKAI (compare Fig 5b, lanes 2 and 3) .
Interestingly, the CD47-induced α4 phosphorylation was also blocked by pertussis toxin, a known inhibitor of Gi, which suggests a Gi dependence of this phosphorylation (Fig 5b) . This is consistent with the known coupling of CD47 to Gi and pertussis toxin-sensitivity of CD47-induced signaling and SS RBC adhesion (27;54). However, CD47-induced signaling did not cause a measurable change in overall cAMP levels in these cells compared to a positive control of forskolin treatment (Fig 5c) , suggesting that the effects of CD47 signaling occur independently of a rise or fall in cAMP formation in SS RBCs. In some cell membranes, Gi fails to couple with adenylate cyclase in an efficient manner (55) . Instead, Gi may preferentially activate Src kinase family members and initiate cell signaling via these enzymes (56) (57) (58) (59) (60) . Consistent with a role for these tyrosine kinases in CD47-induced Gi-mediated signaling, pertussis toxin completely inhibited CD47-induced tyrosine phosphorylation in SS RBCs (Fig 5d) suggesting that activation of both Gi and these kinases are essential for CD47 signal transduction in SS RBCs. Furthermore, incubation of the 4N1K-activated SS RBCs with PKAI also partially blocked CD47-induced tyrosine phosphorylation, further reinforcing a role for a pathway independent of changes in cAMP levels in SS RBCs.
To correlate CD47-induced α4 phosphorylation with CD47-induced SS RBC adhesion, inhibitor completely blocked the stimulated portion of SS RBC adhesion to TSP, whereas preincubation with the control PP3 reagent was without effect (Fig 5f) . Taken Even though CD47 is known to associate with integrins on other cells, an association of CD47 and α4β1 has never been detected in intact cell membranes. Furthermore, in the RBC membrane, CD47 is a part of the Rh complex of proteins (61), which could potentially exclude or disrupt an integrin/CD47 association. We therefore asked whether we could detect an association of CD47 with α4β1 in either unfractionated or density-fractionated SS RBCs.
Unfractionated and unstimulated SS RBCs were lysed and immunoprecipitated for CD47 (Fig   5h, lane 1) or the β1 subunit (Fig 5h, lane 2) of the α4β1 complex and the immunoprecipitates were Western blotted for CD47. CD47 association with β1 was not apparent in the β1 immunoprecipitate prepared from unfractionated SS RBCs (Fig 5h, lane 2, top) or from overestimated amounts of potentially contaminating WBCs (data not shown). However, in density-fractionated SS RBCs, a co-association of CD47 with β1 was readily observed in the low density, reticulocyte-enriched fraction (Fig 5h, lane 2, bottom) , but was not observed in isotype-matched control IgG immunoprecipitates (data not shown). These results suggest that CD47 and α4β1 are physically associated with one another in the reticulocyte population of circulating SS RBCs. These results further suggest a strong, detergent-stable interaction between β1 integrin subunit and CD47 signaling receptor at the SS RBC surface.
Discussion
In this study we show that CD47 stimulates SS RBC binding to immobilized TSP, We also demonstrate that CD47-induced inside-out signaling results in serine phosphorylation of the α4 integrin cytoplasmic domain and that this phosphorylation correlates with the ability of SS RBCs to adhere to immobilized TSP and VCAM-1 under physiological conditions ex vivo.
Our data also indicate that CD47-induced α4β1 activation and adhesion occurs in a PKAdependent manner that is independent of large-scale changes in cAMP levels. Instead, we demonstrate that CD47 signaling in SS RBCs depends on a Gi-mediated activation of the Srcfamily of tyrosine kinases. Finally, we demonstrate that CD47 physically associates with and activates α4β1 most likely by disrupting a cytochalasin D sensitive interaction with the α4β1 integrin and the erythrocyte cytoskeleton. Our results therefore, suggest a novel role for α4β1
on SS RBCs as an "activatable", RGD-binding, adhesive mechanism.
One perplexing question from our study is why CD47 appears to function as an agonist receptor only on SS RBCs, even though it is abundantly expressed on RBCs derived from normal, AA individuals (62). Our finding that CD47 couples to α4β1 in SS RBCs may offer an explanation to this phenomenon. In other cells, CD47 is thought to function only in association with integrins; in fact, the CD47/integrin complex may be essential for CD47 signaling (28).
Since α4β1 is expressed only on the most immature circulating SS RBCs, i.e. reticulocytes, it
can be predicted that CD47 should induce an α4β1-dependent adhesion exclusively in these cells, which are extremely rare in the circulation of normal, AA individuals, but much more abundant in the blood of SCD patients.
Our data also suggest a role for the N-terminal heparin-binding domain, or the NoC1 peptide of TSP, as a potential site to which CD47-stimulated SS RBCs bind. This N-terminal domain, comprised of residues 1-356 from intact TSP, also supports Jurkat T-cell binding via activated α4β1 (15).
Although α4β1 typically binds ligands in an RGD-independent manner, this receptor has been occasionally reported to bind substrates in an RGD-dependent manner (9) . We found that CD47-stimulated SS RBC binding to both immobilized TSP and soluble Fn was completely blocked by an RGD peptide, but not a control RGE peptide. Since SS RBCs do not express any integrin other than α4β1, this RGD-dependence cannot be accounted for by another integrin receptor on these cells. Therefore our data demonstrate for the first time in any cell type a requirement for the RGD site for efficient α4β1-mediated adhesion.
We also observed the activation of SS RBC adhesion by a low concentration of cytochalasin D, which suggests that mild disruption of the erythrocyte cytoskeleton is sufficient to promote adhesivity of these cells. The effects of cytochalasin D on α4β1 activation may mimic PKA-mediated phosphorylation of the α4 subunit, which disrupts the integrin's cytoskeletal attachment to the cytoskeletal protein, paxillin (39) . However, most integrins are known to attach to the cytoskeleton via the cytoplasmic tail of the β subunit (63) . Disruption of this interaction with the cytoskeleton has been demonstrated to activate the αIIbβ3 integrin in platelets (47) and αvβ3 in K562 cells (48) presumably by "releasing" this integrin from its cytoskeletal "restraints", thus allowing a change in conformation to occur. We propose a similar occurrence in SS RBCs and that α4β1 activation in these cells may require contributions from both α subunit phosphorylation and β subunit cytoskeletal linkage.
We also found that the α4 cytoplasmic domain becomes serine-phosphorylated in Because PTX, an inhibitor of Gi, inhibits CD47-stimulated tyrosine phosphorylation in SS RBCs, α4 serine phosphorylation, and SS RBC adhesion to immobilized ligands, Gi appears to be an early and essential component of the CD47 signaling pathway. Therefore, our study is consistent with several other reports that indicate coupling of CD47 directly to this heterotrimeric G-protein, which is expressed in erythrocytes (64) . However, the CD47-induced
Gi signaling in SS RBCs appears to function independent of large scale changes in cAMP levels, but is dependent on PKA activity. At first, these data seem paradoxical, since α4 phosphorylation via CD47 signaling requires both Gi, which inhibits of some isoforms of adenylyl cyclase, and therefore inhibits cAMP formation, and PKA, a downstream effector of cAMP. However, Gi does not inhibit all isoforms of adenylyl cyclase (55) . 
